$IBRX Should the focus be on the expected announcement at AUA that the final review submitted to the FDA was approved and ill patients can now seek reimbursed treatment instead of trial treatment? Those who the SOC could not help now have a good chance of comfortable survival. approval will bring healing and revenue and share ownership interest.